-
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod
Thursday, March 11, 2021 - 6:13am | 341Read More...An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profound efficacy. The antibody treatment is being developed under a collaboration between...
-
Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'
Thursday, February 25, 2021 - 9:57am | 229Read More...Following recommendations from the Independent Data Monitoring Committee (IDMC), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will make changes to the Phase 3 trial evaluating REGEN-COV (casirivimab with imdevimab) in outpatients with COVID-19. The company said that an...
-
Market Wrap For January 7: Markets Reverse 3-Day Slump
Tuesday, January 7, 2014 - 5:39pm | 2743Read More...For the first time in the new year, markets ended the day on a positive note. While it is only a few days in, markets appear to have started off 2014 on uncertain footing. Investors and traders found some positives in the U.S. trade deficit which fell to its lowest level in four years, an...
